U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2021
460
Name Type Language
evinacumab [INN]
Preferred Name English
EVINACUMAB
INN   USAN   WHO-DD  
USAN   INN   JAN  
Official Name English
REGN-1500
Code English
REGN1500
Code English
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROTEIN ANGPTL3 (ANGIOPOIETIN-LIKE 3)) (HUMAN MONOCLONAL REGN1500 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN1500 LIGHT CHAIN, DIMER
Common Name English
EVINACUMAB [USAN]
Common Name English
Evinacumab [WHO-DD]
Common Name English
EVINACUMAB [JAN]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 507815
Created by admin on Mon Mar 31 22:06:36 GMT 2025 , Edited by admin on Mon Mar 31 22:06:36 GMT 2025
Code System Code Type Description
ChEMBL
CHEMBL3545191
Created by admin on Mon Mar 31 22:06:36 GMT 2025 , Edited by admin on Mon Mar 31 22:06:36 GMT 2025
PRIMARY
WIKIPEDIA
Evinacumab
Created by admin on Mon Mar 31 22:06:36 GMT 2025 , Edited by admin on Mon Mar 31 22:06:36 GMT 2025
PRIMARY
NCI_THESAURUS
C169973
Created by admin on Mon Mar 31 22:06:36 GMT 2025 , Edited by admin on Mon Mar 31 22:06:36 GMT 2025
PRIMARY
SMS_ID
100000183292
Created by admin on Mon Mar 31 22:06:36 GMT 2025 , Edited by admin on Mon Mar 31 22:06:36 GMT 2025
PRIMARY
DAILYMED
T8B2ORP1DW
Created by admin on Mon Mar 31 22:06:36 GMT 2025 , Edited by admin on Mon Mar 31 22:06:36 GMT 2025
PRIMARY
DRUG BANK
DB15354
Created by admin on Mon Mar 31 22:06:36 GMT 2025 , Edited by admin on Mon Mar 31 22:06:36 GMT 2025
PRIMARY
RXCUI
2478335
Created by admin on Mon Mar 31 22:06:36 GMT 2025 , Edited by admin on Mon Mar 31 22:06:36 GMT 2025
PRIMARY
INN
10013
Created by admin on Mon Mar 31 22:06:36 GMT 2025 , Edited by admin on Mon Mar 31 22:06:36 GMT 2025
PRIMARY
USAN
BC-26
Created by admin on Mon Mar 31 22:06:36 GMT 2025 , Edited by admin on Mon Mar 31 22:06:36 GMT 2025
PRIMARY
CAS
1446419-85-7
Created by admin on Mon Mar 31 22:06:36 GMT 2025 , Edited by admin on Mon Mar 31 22:06:36 GMT 2025
PRIMARY
FDA UNII
T8B2ORP1DW
Created by admin on Mon Mar 31 22:06:36 GMT 2025 , Edited by admin on Mon Mar 31 22:06:36 GMT 2025
PRIMARY
ACTIVE MOIETY
EVINACUMAB
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966